From Financial Modeling Prep: 2025-05-08 06:00:00

Takeda Pharmaceutical Company Limited, a global biopharmaceutical leader, reported an EPS of -$0.23, missing the estimate of -$0.03, signaling challenges in meeting market expectations. Despite revenue of $7.34 billion, below the expected $8.02 billion, Takeda showed growth and increased Core Operating Profit for fiscal year 2024. With a debt-to-equity ratio of 0.73 and a current ratio of 1.28, Takeda demonstrates moderate debt levels and strong short-term liability coverage.



Read more at Financial Modeling Prep:: Takeda Pharmaceutical Company Limited (NYSE:TAK) F…